CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma
-
Published:2020-06-08
Issue:5
Volume:123
Page:833-843
-
ISSN:0007-0920
-
Container-title:British Journal of Cancer
-
language:en
-
Short-container-title:Br J Cancer
Author:
Mo Xue-Tang,Leung Thomas Ho-Yin,Tang Hermit Wai-Man,Siu Michelle Kwan-Yee,Wan Peter Kok-Ting,Chan Karen Kar-Loen,Cheung Annie Nga-Yin,Ngan Hextan Yuen-Sheung
Abstract
Abstract
Background
CD109 was involved in the tumorigenesis and progression of various cancers via TGF-β1 signalling and STAT3 activation. As CD109 is strongly expressed in cervical squamous cell carcinoma, this study was conducted to investigate its functional characteristics in cervical cancer.
Methods
CD109 expression was examined by immunohistochemistry (IHC) with cervical tissue microarray. The effects of CD109 expression were examined on migration, cell proliferation, spheroid formation and soft-agar colony-formation assay. Meanwhile, cervical cancer cell lines with high CD109 expression were chosen for the functional study using siRNA knockdown and CRISPR/Cas9 knockout.
Results
IHC demonstrated an upregulation of CD109 in the cell membrane of cervical squamous cell carcinoma. CD109( + ) cells isolated by flow-cytometric sorting displayed enhanced migration, cell proliferation, sphere-forming and anchorage-independent cell growth ability. In contrast, silencing of CD109 expression could reverse the in vitro and in vivo tumorigenic and aggressive properties. Furthermore, CD109 induced EGFR-mediated STAT3 phosphorylation known to be responsible for cell migration, proliferation and maintenance of CSC phenotype.
Conclusion
Abundant CD109( + ) populations in cervical cancer cells potentially contributed to carcinogenesis and aggressiveness, whereas silencing of CD109 expression could reverse those properties. CD109 mediates cervical tumorigenicity and aggressiveness via CD109/EGFR/STAT3 signalling.
Funder
This work was supported by the Seed Funding Programme for Basic Research, The University of Hong Kong.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference50 articles.
1. Lin, M., Sutherland, D. R., Horsfall, W., Totty, N., Yeo, E., Nayar, R. et al. Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 99, 1683–1691 (2002). 2. Haun, R. S., Fan, C. Y., Mackintosh, S. G., Zhao, H. & Tackett, A. J. CD109 overexpression in pancreatic cancer identified by cell-surface glycoprotein capture. J. Proteom. Bioinform. Suppl 10, S10003 (2014). 3. Zong, G., Xu, Z., Zhang, S., Shen, Y., Qiu, H., Zhu, G. et al. CD109 mediates cell survival in hepatocellular carcinoma cells. Dig. Dis. Sci. 61, 2303–2314 (2016). 4. Ohshima, Y., Yajima, I., Kumasaka, M. Y., Yanagishita, T., Watanabe, D., Takahashi, M. et al. CD109 expression levels in malignant melanoma. J. Dermatol. Sci. 57, 140–142 (2010). 5. Zhang, J. M., Hashimoto, M., Kawai, K., Murakumo, Y., Sato, T., Ichihara, M. et al. CD109 expression in squamous cell carcinoma of the uterine cervix. Pathol. Int. 55, 165–169 (2005).
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|